RE:1b results?The release of data was mentioned in the closing remark of 2022 Q2 meeting. Below is the excerpt.
From my perspective, the interim data will be likely released prior to 2022Q3 meeting which will be held in mid October, so they can talk about it on the meeting.
The second important takeaway is that we have successfully reached the end of the dose escalation portion in TH1902, and have established our go-forward dose. We now expect new data to be potentially released in the back half of 2022 with regards to early efficacy of our basket trial. This will be followed in Q1 of 2023 by a presentation of the complete data set for the dose escalation study, which has already established dose limiting toxicity in addition to the go-forward dose.